Abstract
Addressing the uncontrollable factors influencing the European biotech market is critical to the commercial success of emerging biotech companies, as the accelerating pace of biotechnological research allows for the development and implementation of new products and services. Modern biotechnology demands rigorous oversight of macroenvironmental factors, as each of these uncontrollable macroenvironmental factors affect new ventures in biotech; change occurs when companies manage to favorably respond to the challenges imposed by each factor, constructing a different representation for the public, and thus shaping the development of biotechnology itself.
With biotechnology used in a wide variety of sectors, it is imperative to analyze market factors in several fields, with focus on one hand on specific European factors and on the other hand on global factors that either pose threats or opportunities for new ventures.
As in all cases, factors of the macroenvironment are beyond the influence capacities of individual companies and will always present themselves as either opportunities or threats. Given the specificity of biotechnology, there will always be needs that are not catered to.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aerni P, Gagalac F, Scholderer J (2015) The role of biotechnology in combating climate change: a question of politics? Sci Public Policy 43(1):13–28
Amin L, Jahi JM, Nor ARM, Osman M, Mahadi NM (2007) Public acceptance of modern biotechnology. Asia Pac J Mol Biol Biotechnol 15(2):39–51
Bernauer T, Meins E (2003) Technological revolution meets policy and the market: explaining cross-national differences in agricultural biotechnology regulation. Eur J Polit Res 42(5):643–683
Gaskell G, Alum N, Baouer M, Durant J, Allansdottir A, Bonfadelli H, Boy D, Cheveigne DS, Fjaestad B, Gutteling JM, Hampel J, Jelsoe E, Jesuino JG, Kohring M, Kronberger N, Midden C, Nielsen TH, Przestalski A, Rusanen T, Sakellaris G, Torgersen H, Twardowski T, Wagner W (2000) Biotechnology and the European public. Nat Biotechnol (18):935–938
Internet World Stats (2019). https://www.internetworldstats.com/europa2.htm. Accessed 10 Mar 2019
Kearney C (2018) Regulation and market influences on innovation in biotechnology. J Commer Biotechnol 24(3):57–62
Knight ERW (2010) The economic geography of clean tech venture capital. Oxford University Working Paper Series in Employment, Work and Finance. Available at SSRN: https://ssrn.com/abstract=1588806 or doi:https://doi.org/10.2139/ssrn.1588806
Kotler P, Armstrong G (2015) Principles of marketing-global edition. Pearson
Kurzer P, Cooper A (2007) Consumer activism, EU institutions and global markets: the struggle over biotech foods. J Public Policy 27(2):103–128
Pardo R, Calvo F (2006) Are Europeans really antagonistic to biotech? Nat Biotechnol 24(4):393–396
Savadori L, Savio S, Nicotra E, Rumiati R, Finucane M, Slovic P (2004) Expert and public perception of risk from biotechnology. Risk Anal 24(5):1289–1299
Tiago MTPMB, VerÃssimo JMC (2014) Digital marketing and social media: Why bother? Bus Horiz 57(6):703–708
Tyagi P, Kumar A, Sengar RS (2018) The opportunities to develop a successful entrepreneurship and business model in biotechnology: an overview. J Commer Biotechnol 24(3):63–68
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Perju-Mitran, A. (2019). Key Elements of the Biotech Market. In: Matei, F., Zirra, D. (eds) Introduction to Biotech Entrepreneurship: From Idea to Business. Springer, Cham. https://doi.org/10.1007/978-3-030-22141-6_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-22141-6_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-22140-9
Online ISBN: 978-3-030-22141-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)